Table 1.
Time to onset (min) |
Duration (min) |
|||
Male | Female | Male | Female | |
Alfaxalone | 2.4 ± 0.5 | 2.2 ± 0.4 | 46.0 ± 3.3a | 67.0 ± 5.5a,b |
Ketamine | 5.3 ± 1.7c | 5.6 ± 0.9c | 8.8 ± 2.2 | 5.4 ± 1.5 |
Alfaxalone + xylazine | 2.3 ± 0.2 | 2.3 ± 0.2 | 73.1 ± 5.6d | 89.8 ± 6.6d |
Ketamine + xylazine | 4.1 ± 0.4e | 4.0 ± 0.4e | 39.9 ± 3.1 | 34.2 ± 2.2 |
Significantly (P < 0.001) greater than corresponding value in ketamine-treated mice of same sex.
Significantly (P = 0.02) greater than corresponding value in alfaxalone-treated male mice.
Significantly (P < 0.001) greater than corresponding value in alfaxalone-treated mice of same sex.
Significantly (P < 0.0001) greater than corresponding value in mice of same sex treated with ketamine and xylazine.
Significantly (P < 0.001) greater than corresponding value in mice of same sex treated with ketamine and xylazine.